Faivre-Finn Corinne, Lorigan Paul, West Catharine, Thatcher Nick
Clinical Oncology Department, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK.
Clin Lung Cancer. 2005 Jul;7(1):23-9. doi: 10.3816/CLC.2005.n.018.
The role of thoracic radiation therapy (RT; TRT) is now established in the management of limited-stage small-cell lung cancer (SCLC). There is increasing evidence in the literature in favor of early concurrent chemoradiation therapy, and a gold standard of care for patients with a good performance status is twice-daily TRT (45 Gy in 3 weeks) with concurrent cisplatin/etoposide. Five-year survival rates > 20% can be expected with this combined-modality approach. Although current clinical trials are exploring the efficacy of new chemotherapeutic strategies for the disease, essential questions related to the optimization of TRT remain unanswered. In particular, the optimal RT dose, fractionation, and treatment volume have not been defined. This review highlights the need for well-designed multinational trials aimed at the optimization and standardization of RT for limited-stage SCLC. These trials should integrate translational research studies to investigate the molecular basis of RT resistance and to develop biomarker profiles of prognosis.
胸部放射治疗（RT；TRT）在局限期小细胞肺癌（SCLC）的治疗中作用已得到确立。文献中越来越多的证据支持早期同步放化疗，对于身体状况良好的患者，标准治疗方案是每日两次的TRT（3周内45 Gy）联合顺铂/依托泊苷同步化疗。采用这种综合治疗方法有望实现> 20%的五年生存率。尽管目前的临床试验正在探索针对该疾病的新化疗策略的疗效，但与TRT优化相关的关键问题仍未得到解答。特别是，最佳放疗剂量、分割方式和治疗体积尚未确定。本综述强调需要开展精心设计的多国试验，旨在优化局限期SCLC的放疗并使其标准化。这些试验应整合转化研究，以探究放疗抵抗的分子基础并开发预后生物标志物谱。
